Drug Delivery Technology Market
Advancements in Biopharmaceuticals and Patient Care to act as a major growth lever for Drug Delivery Technology Developments
Drug Delivery Technology Market by Route of Administration, End User, Region - Forecast 2022-2032
Drug Delivery Technology Market Snapshot (2022-2032)
[299 Pages Report] The global drug delivery technology market is expected to be valued at US$ 39,330 Million in 2022. Increasing adoption of advanced technology for effectively delivering the drug to the target site is expected to drive overall market growth. The overall demand for drug delivery technology is projected to grow at a CAGR of 13.3% between 2022 and 2032, totaling around 137,615.91 Million by 2032.
A drug delivery system is a process of administering a therapeutic substance through the common route of administration to achieve a therapeutic effect in humans or animals. Drugs release the active ingredients in the target area so that in the period it controls through its formulation.
The most important driving factor for the drug delivery technology market is the increasing demand for effective delivery mechanisms of novel biopharmaceuticals.
|
Data Points |
Key Statistics |
|
Drug Delivery Technology Market Value 2022 |
US$ 39,330 Million |
|
Drug Delivery Technology Market Projected Value (2032) |
US$ 137,615.91 Million |
|
Drug Delivery Technology Market CAGR (2022-2032) |
13.3% |
Recently, AstraZeneca signed a licensing agreement with Starpharma for the use of its DEP drug delivery technology aiming to enhance the dosing and efficacy characteristics of pharmaceuticals. AstraZeneca agreed to fund all development and commercialization costs, including ongoing and future collaborative work conducted with Starpharma.
Let us know your requirement to get
100% FREE customization
Drug Delivery Technology Demand Analysis (2016 To 2021) Vs Market Outlook (2022 To 2032)
The global demand for drug delivery technology is projected to increase at a CAGR of 13.3% during the forecast period between 2022 and 2032, reaching a total of US$ 137,615.91 Million in 2032, according to a report from Future Market Insights (FMI). From 2016 to 2021, sales witnessed significant growth, registering a CAGR of 10.5%.
The drug delivery technology market has grown substantially at a healthy CAGR due to the growing incidence of chronic diseases and lifestyle changes. With rapid technological advancement and innovation, the drug delivery technology market is expected to grow globally.
In addition, the increasing prevalence of chronic diseases in regions like North America and Europe has boosted the demand for drug delivery technology. According to Rand.org, almost 60 percent of American adults currently live with at least one chronic condition 42 percent have more than one.
They account for hundreds of billions of dollars in health care spending every year. Owing to these factors, the market for drug delivery technology is projected to experience exceptional growth over the forecast period.
Drug Delivery Technology Market: Drivers & Restraints
Growing incidence of chronic diseases such as cardiovascular diseases, diabetes, and cancer, technological advancement, innovation, the growing focus on pediatric and geriatric patients, change in lifestyle due to growing urbanization, the increasing demand for minimally invasive surgeries, are the most important driving factors in drug delivery technology market. Since growth of biopharmaceutical market is fast, the demand for drug delivery technology market has increased.
With so many advantages and splendid features of drug delivery technology, it has few disadvantages too. Side-effects related to drugs, patents expiry and regulatory hurdles are acting as key barrier for drug delivery technology.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich Drivers Underpin Drug Delivery Technology Industry Expansion?
Rising Prevalence of Chronic Diseases & Surplus Investments in R&D to Act as Primary Growth Drivers
Growing incidence of chronic diseases such as cardiovascular diseases, diabetes, and cancer, technological advancement, innovation, the growing focus on pediatric and geriatric patients, change in lifestyle due to growing urbanization, and the increasing demand for minimally invasive surgeries, are the most important driving factors in drug delivery technology market. Since the growth of the biopharmaceutical market is fast, the demand for the drug delivery technology market has increased.
Swelling demand for novel drug delivery devices is expected to advance R&D in the field. Key market players are incessantly engaged in strategic alliances to develop advanced technology for various applications.
In January 2021, AstraZeneca collaborated with Aptamer Group, a biotechnology company for exploring its technology to develop a novel drug delivery device for a kidney. In addition, the increasing adoption of drug delivery devices in home-care settings is snowballing the accessibility of these devices for patients.
What Are The Challenges Faced By Drug Delivery Technology Industry?
Uncontrolled Intake of Medicine May Lead to Certain Side effects likely to Impede Market Growth
Despite the advantages and advancements associated with these drug delivery devices, certain challenges are expected to hinder the market growth. The major challenge faced with this drug delivery device is its inefficiency in delivering poorly soluble drugs.
Furthermore, other bioavailability hurdles of poorly soluble drugs are also expected to impact market growth. In addition, these drug delivery devices may release uncontrolled drugs on the infection site which can later lead to other side effects such as infections and allergies.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Region-Wise Insights
Will North America Hold a Significant Position in the Global Drug Delivery Technology Market?
Rising Awareness Regarding the Novel Advancements & Presence of Prominent Players to Put Region at the Forefront
In terms of regional platforms, North America holds a significant market share in the Drug Delivery Technology market. The region is expected to surge at over 37.5% share in 2022 and is projected to maintain its lead over the forecast period due to its preference for printing by thermal label manufacturers. The United States & Canada account for the majority share of the regional revenue contribution.
This market growth is attributed to the presence of prominent players in the region and the growing adoption of drug delivery devices. Besides, rising awareness in the region regarding the advantages of drug delivery devices is also likely to boost the market growth in the region.
In addition, growing product approval in countries such as the U.S. is also projected to contribute to market growth. In March 2019, Aptar Pharma received U.S. FDA approval for a nasal drug delivery device.
The increasing burden of chronic diseases such as cancer, diabetes, and cardiac disorders is aiding the market growth. According to the American Diabetes Association (ADA), 34.2 million Americans had diabetes in 2020, out of which 26.8 million were diagnosed and 7.3 million were undiagnosed. Consequently, an increasing number of diagnosed diabetes cases is anticipated to contribute toward the adoption of drug delivery devices in the field of diabetes.
How Will Growth of the European Drug Delivery Technology Market unfold?
Availability of Exceptional Healthcare Infrastructure to Boost Regional Revenue Share
According to Future Market Insights, Europe is expected to provide immense growth opportunities for Drug Delivery Technology and is expected to reach the highest share of 33.6% in 2022. This market growth is attributed to growing research and developmental activities and the presence of key pharmaceutical companies in the region.
With the significant surge in patients suffering from chronic diseases such as cancer, diabetes, and COPD, the regional market is subject to tread along a stellar growth track over the coming years.
In Nov 2021, Baxter International Inc., a global leader in sterile medication production and delivery, announced an approximately US$100 million expansion of its sterile fill/finish manufacturing facility located in Halle/Westfalen, Germany. Thereby, surplus investments by key players in research facilities have propelled the market growth for drug delivery technology.
How will Asia Pacific Bolster the Demand for Drug Delivery Technology?
Expanding Geriatric Population one of the Significant Causes of the Development of Drug Delivery Technology
As per the recent analysis by Future Market Insights, Asia pacific is anticipated to be the highest growing region over the forecast period. A large patient pool in countries like Japan, China, and India is also leading to the adoption of drug delivery devices by several end-users. In addition, in Japan, distinctive types of drug delivery devices are being introduced for delivering specific types of drugs.
In December 2019, the YpsoMate autoinjector was launched in the Japanese market for accurate delivery of Teribone drug. Thus, the growing adoption of advanced drug delivery devices in the region is expected to boost market growth during the forecast period.
Along with this, regional players are doing mergers and acquisitions to expand their product portfolio and increase market reach. For instance, Pfizer Inc. and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, today announced they have entered into a Development and Option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development.
Category-Wise Insights
By Route of Administration, which Drug Delivery Technology Category will remain Prominent?
Based on route of administration, the oral route of administration subtype captures the highest share in 2022 and is expected to be the fastest growing segment of the Drug Delivery Technology market during the forecast period.
The oral drug delivery system comprises an extensive range of dosage forms including tablets, capsules, syrups, solutions, and suspensions. This segment also contains drug delivery products such as films and tablets. The oral route is the preferred route of administration in terms of safety, ease of use, cost, and drug stability.
Inhalation drug delivery systems are considered ideal in cases of pulmonary conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD). Aspects such as the growing prevalence of respiratory diseases and the technological development of devices used for inhalation delivery such as nebulizers and inhalers are anticipated to propel the growth of this segment.
The injectable route of administration is likely to expand at the fastest growth rate throughout the forecast period. Progressions in injectable drug delivery systems, such as the advent of prefilled syringes and pen injectors, have augmented the demand in the past two to three years. Additionally, the development of materials for syringes such as polymers, which are inert to most chemicals, is stimulating market growth.
The Start-Up Ecosystem
How key Players are Opening Frontiers for Future Growth?
There are many prominent market players in the Drug Delivery Technology market, who are working hand-in-hand to provide the best-in-class Drug Delivery Technology for enhancing the global analytics arena.
However, many global start-ups in the Drug Delivery Technology market are stepping forward in matching the requirements of the Drug Delivery Technology domain.
- Founded in 2001, CROSSJECT developed a needle-free injection platform called Zeneo, which is designed to improve patient safety, claimed to provide comfort, and enable a better observance of treatments. The product is a pre-fillable, needle-free injection system that is claimed to deliver drugs intradermally, subcutaneously, and intramuscularly. As of Jan 2017, the company is developing a portfolio of products combining well-known drugs with an innovative injection mode, particularly adapted to emergencies and most chronic treatments, with a device adaptable to many specific situations. To date, the company recorded annual revenues of US$ 40 million and is based out of Dijon (France).
- Founded in 2013, AFYX Therapeutics is a developer of drug patches for the treatment of mucosal diseases. It has developed Rivelin which is a self-adhesive drug patch that is designed to deliver uniform doses of therapy to the mucosal lining. The company's lead product candidate Rivelin-CLO is used against oral lichen planus. The startup is located in Copenhagen (Denmark) and gathered overall funding of US$ 33 Billion to date.
- Founded in 2013, SC Pharmaceuticals is a provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure. The company has developed a device called sc2Wear Pump that facilitates subcutaneous drug administration over durations, rates, and volumes that can be tailored to specific drugs. The pipeline includes Furosemide for heart failure, Ceftriaxone, and Ertapenem to treat bacterial infections. The company is based out of
Lexington, Massachusetts, United States, and received overall funding of nearly US$ 20 Million.
Competitive Landscape
What are the Leading Players in the Drug Delivery Technology Market Up to?
- In December 2021, Johnson & Johnson announced the acquisition of TARIS Biomedical LLC (TARIS), a privately-owned biotechnology company specializing in the development of a novel drug delivery technology for the treatment of bladder diseases including cancer. The company's lead clinical-stage product, TAR-200, uses the proprietary TARIS System, which features a silicone-based drug delivery device that allows for the continuous release of medication into the bladder.
- In May 2021, 3M announced that it has completed the sale of substantially all of its drug delivery business to an affiliate of Altaris Capital Partners, LLC., for approximately US$ 650 Billion in total consideration, including cash, interest-bearing security, and a 17 percent non-controlling interest in the new company, Kindeva Drug Delivery, that will operate the business.
- In August 2022, Merck has tightened its ties to Starpharma as it continues to build out its antibody-drug conjugate (ADC) capabilities, signing a second agreement that will enable it to evaluate candidates based on a dendrimer drug delivery platform.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 13.3% from 2022-2032 |
|
Market Value in 2022 |
US$ 39,330 Million |
|
Market Value in 2032 |
US$ 137,615.91 Million |
|
Base Year for Estimates |
2021 |
|
Historical Data |
2016-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in US$ Million and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
Key Segments Covered In The Drug Delivery Technology Industry Analysis
Drug Delivery Technology Market by Route of Administration:
- Oral Route
- Parenteral Route
- Intramuscular
- Intravenous
- Intra-arterial
- Subcutaneous route
- Transdermal Route
- Inhalation Route
- Nasal Drug Delivery
Drug Delivery Technology Market by End User:
- Hospitals
- Clinics
- Diagnostic Centres
- Home care settings
- Others
Drug Delivery Technology Market by Region:
- North America Drug Delivery Technology Market
- Latin America Drug Delivery Technology Market
- Europe Drug Delivery Technology Market
- Asia Pacific Drug Delivery Technology Market
- Middle East & Africa Drug Delivery Technology Market
Frequently Asked Questions
What is the expected market value for drug delivery technology in 2022?
As of 2022, the drug delivery technology market is slated to reach a valuation of US$ 39,330 Million
At what rate will the drug delivery technology market flourish from 2022-2032?
From 2022-2032, sales of drug delivery technology are expected to grow at a 13.3% CAGR
What is the expected market value for drug delivery technology in 2032?
By 2032, Future Market Insights expects the Drug Delivery Technology market to reach US$ 137,615.91 Million
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2016-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) Analysis, 2016-2021 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Route of Administration 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2016-2021 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032 5.3.1. Oral Route 5.3.2. Parenteral Route 5.3.2.1. Intramuscular 5.3.2.2. Intravenous 5.3.2.3. Intra-arterial 5.3.2.4. Subcutaneous Route 5.3.3. Transdermal Route 5.3.4. Inhalation Route 5.3.5. Nasal Drug Delivery 5.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2016-2021 5.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032 6. Global Market Analysis 2016-2021 and Forecast 2022-2032, By End User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2016-2021 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032 6.3.1. Hospitals 6.3.2. Clinics 6.3.3. Diagnostic Centres 6.3.4. Home Care Settings 6.3.5. Others 6.4. Y-o-Y Growth Trend Analysis By End User, 2016-2021 6.5. Absolute $ Opportunity Analysis By End User, 2022-2032 7. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2016-2021 7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. Asia Pacific 7.3.5. MEA 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2016-2021 and Forecast 2022-2032, By Country 8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021 8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 8.2.1. By Country 8.2.1.1. US 8.2.1.2. Canada 8.2.2. By Route of Administration 8.2.3. By End User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Route of Administration 8.3.3. By End User 8.4. Key Takeaways 9. Latin America Market Analysis 2016-2021 and Forecast 2022-2032, By Country 9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021 9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Route of Administration 9.2.3. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Route of Administration 9.3.3. By End User 9.4. Key Takeaways 10. Europe Market Analysis 2016-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. U.K. 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Route of Administration 10.2.3. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Route of Administration 10.3.3. By End User 10.4. Key Takeaways 11. Asia Pacific Market Analysis 2016-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.1.4. Rest of Asia Pacific 11.2.2. By Route of Administration 11.2.3. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Route of Administration 11.3.3. By End User 11.4. Key Takeaways 12. MEA Market Analysis 2016-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. GCC Countries 12.2.1.2. South Africa 12.2.1.3. Israel 12.2.1.4. Rest of MEA 12.2.2. By Route of Administration 12.2.3. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Route of Administration 12.3.3. By End User 12.4. Key Takeaways 13. Key Countries Market Analysis 13.1. US 13.1.1. Pricing Analysis 13.1.2. Market Share Analysis, 2021 13.1.2.1. By Route of Administration 13.1.2.2. By End User 13.2. Canada 13.2.1. Pricing Analysis 13.2.2. Market Share Analysis, 2021 13.2.2.1. By Route of Administration 13.2.2.2. By End User 13.3. Brazil 13.3.1. Pricing Analysis 13.3.2. Market Share Analysis, 2021 13.3.2.1. By Route of Administration 13.3.2.2. By End User 13.4. Mexico 13.4.1. Pricing Analysis 13.4.2. Market Share Analysis, 2021 13.4.2.1. By Route of Administration 13.4.2.2. By End User 13.5. Germany 13.5.1. Pricing Analysis 13.5.2. Market Share Analysis, 2021 13.5.2.1. By Route of Administration 13.5.2.2. By End User 13.6. U.K. 13.6.1. Pricing Analysis 13.6.2. Market Share Analysis, 2021 13.6.2.1. By Route of Administration 13.6.2.2. By End User 13.7. France 13.7.1. Pricing Analysis 13.7.2. Market Share Analysis, 2021 13.7.2.1. By Route of Administration 13.7.2.2. By End User 13.8. Spain 13.8.1. Pricing Analysis 13.8.2. Market Share Analysis, 2021 13.8.2.1. By Route of Administration 13.8.2.2. By End User 13.9. Italy 13.9.1. Pricing Analysis 13.9.2. Market Share Analysis, 2021 13.9.2.1. By Route of Administration 13.9.2.2. By End User 13.10. China 13.10.1. Pricing Analysis 13.10.2. Market Share Analysis, 2021 13.10.2.1. By Route of Administration 13.10.2.2. By End User 13.11. Japan 13.11.1. Pricing Analysis 13.11.2. Market Share Analysis, 2021 13.11.2.1. By Route of Administration 13.11.2.2. By End User 13.12. South Korea 13.12.1. Pricing Analysis 13.12.2. Market Share Analysis, 2021 13.12.2.1. By Route of Administration 13.12.2.2. By End User 13.13. GCC Countries 13.13.1. Pricing Analysis 13.13.2. Market Share Analysis, 2021 13.13.2.1. By Route of Administration 13.13.2.2. By End User 13.14. South Africa 13.14.1. Pricing Analysis 13.14.2. Market Share Analysis, 2021 13.14.2.1. By Route of Administration 13.14.2.2. By End User 13.15. Israel 13.15.1. Pricing Analysis 13.15.2. Market Share Analysis, 2021 13.15.2.1. By Route of Administration 13.15.2.2. By End User 14. Market Structure Analysis 14.1. Competition Dashboard 14.2. Competition Benchmarking 14.3. Market Share Analysis of Top Players 14.3.1. By Regional 14.3.2. By Route of Administration 14.3.3. By End User 15. Competition Analysis 15.1. Competition Deep Dive 15.1.1. Johnson and Johnson 15.1.1.1. Overview 15.1.1.2. Product Portfolio 15.1.1.3. Profitability by Market Segments 15.1.1.4. Sales Footprint 15.1.1.5. Strategy Overview 15.1.1.5.1. Marketing Strategy 15.1.2. 3M 15.1.2.1. Overview 15.1.2.2. Product Portfolio 15.1.2.3. Profitability by Market Segments 15.1.2.4. Sales Footprint 15.1.2.5. Strategy Overview 15.1.2.5.1. Marketing Strategy 15.1.3. Novartis AG 15.1.3.1. Overview 15.1.3.2. Product Portfolio 15.1.3.3. Profitability by Market Segments 15.1.3.4. Sales Footprint 15.1.3.5. Strategy Overview 15.1.3.5.1. Marketing Strategy 15.1.4. Pfizer Inc. 15.1.4.1. Overview 15.1.4.2. Product Portfolio 15.1.4.3. Profitability by Market Segments 15.1.4.4. Sales Footprint 15.1.4.5. Strategy Overview 15.1.4.5.1. Marketing Strategy 15.1.5. Glaxosmithkline 15.1.5.1. Overview 15.1.5.2. Product Portfolio 15.1.5.3. Profitability by Market Segments 15.1.5.4. Sales Footprint 15.1.5.5. Strategy Overview 15.1.5.5.1. Marketing Strategy 15.1.6. Merck & Co. 15.1.6.1. Overview 15.1.6.2. Product Portfolio 15.1.6.3. Profitability by Market Segments 15.1.6.4. Sales Footprint 15.1.6.5. Strategy Overview 15.1.6.5.1. Marketing Strategy 15.1.7. Antares Pharma 15.1.7.1. Overview 15.1.7.2. Product Portfolio 15.1.7.3. Profitability by Market Segments 15.1.7.4. Sales Footprint 15.1.7.5. Strategy Overview 15.1.7.5.1. Marketing Strategy 15.1.8. Generex Biotechnology 15.1.8.1. Overview 15.1.8.2. Product Portfolio 15.1.8.3. Profitability by Market Segments 15.1.8.4. Sales Footprint 15.1.8.5. Strategy Overview 15.1.8.5.1. Marketing Strategy 15.1.9. EyePoint Pharmaceuticals 15.1.9.1. Overview 15.1.9.2. Product Portfolio 15.1.9.3. Profitability by Market Segments 15.1.9.4. Sales Footprint 15.1.9.5. Strategy Overview 15.1.9.5.1. Marketing Strategy 15.1.10. Alkerme 15.1.10.1. Overview 15.1.10.2. Product Portfolio 15.1.10.3. Profitability by Market Segments 15.1.10.4. Sales Footprint 15.1.10.5. Strategy Overview 15.1.10.5.1. Marketing Strategy 15.1.11. Becton, Dickinson and Company 15.1.11.1. Overview 15.1.11.2. Product Portfolio 15.1.11.3. Profitability by Market Segments 15.1.11.4. Sales Footprint 15.1.11.5. Strategy Overview 15.1.11.5.1. Marketing Strategy 15.1.12. Vectura Group 15.1.12.1. Overview 15.1.12.2. Product Portfolio 15.1.12.3. Profitability by Market Segments 15.1.12.4. Sales Footprint 15.1.12.5. Strategy Overview 15.1.12.5.1. Marketing Strategy 15.1.13. NanoPass Technologies Ltd 15.1.13.1. Overview 15.1.13.2. Product Portfolio 15.1.13.3. Profitability by Market Segments 15.1.13.4. Sales Footprint 15.1.13.5. Strategy Overview 15.1.13.5.1. Marketing Strategy 15.1.14. Baxter 15.1.14.1. Overview 15.1.14.2. Product Portfolio 15.1.14.3. Profitability by Market Segments 15.1.14.4. Sales Footprint 15.1.14.5. Strategy Overview 15.1.14.5.1. Marketing Strategy 15.1.15. Gerresheimer AG 15.1.15.1. Overview 15.1.15.2. Product Portfolio 15.1.15.3. Profitability by Market Segments 15.1.15.4. Sales Footprint 15.1.15.5. Strategy Overview 15.1.15.5.1. Marketing Strategy 16. Assumptions & Acronyms Used 17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Value (US$ Mn) Forecast by Region, 2016-2032 Table 02: Global Market Value (US$ Mn) Forecast by Route of Administration, 2016-2032 Table 03: Global Market Value (US$ Mn) Forecast by End User, 2016-2032 Table 04: North America Market Value (US$ Mn) Forecast by Country, 2016-2032 Table 05: North America Market Value (US$ Mn) Forecast by Route of Administration, 2016-2032 Table 06: North America Market Value (US$ Mn) Forecast by End User, 2016-2032 Table 07: Latin America Market Value (US$ Mn) Forecast by Country, 2016-2032 Table 08: Latin America Market Value (US$ Mn) Forecast by Route of Administration, 2016-2032 Table 09: Latin America Market Value (US$ Mn) Forecast by End User, 2016-2032 Table 10: Europe Market Value (US$ Mn) Forecast by Country, 2016-2032 Table 11: Europe Market Value (US$ Mn) Forecast by Route of Administration, 2016-2032 Table 12: Europe Market Value (US$ Mn) Forecast by End User, 2016-2032 Table 13: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2016-2032 Table 14: Asia Pacific Market Value (US$ Mn) Forecast by Route of Administration, 2016-2032 Table 15: Asia Pacific Market Value (US$ Mn) Forecast by End User, 2016-2032 Table 16: MEA Market Value (US$ Mn) Forecast by Country, 2016-2032 Table 17: MEA Market Value (US$ Mn) Forecast by Route of Administration, 2016-2032 Table 18: MEA Market Value (US$ Mn) Forecast by End User, 2016-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Market Value (US$ Mn) by Route of Administration, 2022-2032 Figure 02: Global Market Value (US$ Mn) by End User, 2022-2032 Figure 03: Global Market Value (US$ Mn) by Region, 2022-2032 Figure 04: Global Market Value (US$ Mn) Analysis by Region, 2016-2032 Figure 05: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032 Figure 06: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032 Figure 07: Global Market Value (US$ Mn) Analysis by Route of Administration, 2016-2032 Figure 08: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032 Figure 09: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032 Figure 10: Global Market Value (US$ Mn) Analysis by End User, 2016-2032 Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2022-2032 Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2022-2032 Figure 13: Global Market Attractiveness by Route of Administration, 2022-2032 Figure 14: Global Market Attractiveness by End User, 2022-2032 Figure 15: Global Market Attractiveness by Region, 2022-2032 Figure 16: North America Market Value (US$ Mn) by Route of Administration, 2022-2032 Figure 17: North America Market Value (US$ Mn) by End User, 2022-2032 Figure 18: North America Market Value (US$ Mn) by Country, 2022-2032 Figure 19: North America Market Value (US$ Mn) Analysis by Country, 2016-2032 Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 22: North America Market Value (US$ Mn) Analysis by Route of Administration, 2016-2032 Figure 23: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032 Figure 24: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032 Figure 25: North America Market Value (US$ Mn) Analysis by End User, 2016-2032 Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2022-2032 Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2022-2032 Figure 28: North America Market Attractiveness by Route of Administration, 2022-2032 Figure 29: North America Market Attractiveness by End User, 2022-2032 Figure 30: North America Market Attractiveness by Country, 2022-2032 Figure 31: Latin America Market Value (US$ Mn) by Route of Administration, 2022-2032 Figure 32: Latin America Market Value (US$ Mn) by End User, 2022-2032 Figure 33: Latin America Market Value (US$ Mn) by Country, 2022-2032 Figure 34: Latin America Market Value (US$ Mn) Analysis by Country, 2016-2032 Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 37: Latin America Market Value (US$ Mn) Analysis by Route of Administration, 2016-2032 Figure 38: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032 Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032 Figure 40: Latin America Market Value (US$ Mn) Analysis by End User, 2016-2032 Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2022-2032 Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2022-2032 Figure 43: Latin America Market Attractiveness by Route of Administration, 2022-2032 Figure 44: Latin America Market Attractiveness by End User, 2022-2032 Figure 45: Latin America Market Attractiveness by Country, 2022-2032 Figure 46: Europe Market Value (US$ Mn) by Route of Administration, 2022-2032 Figure 47: Europe Market Value (US$ Mn) by End User, 2022-2032 Figure 48: Europe Market Value (US$ Mn) by Country, 2022-2032 Figure 49: Europe Market Value (US$ Mn) Analysis by Country, 2016-2032 Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 52: Europe Market Value (US$ Mn) Analysis by Route of Administration, 2016-2032 Figure 53: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032 Figure 54: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032 Figure 55: Europe Market Value (US$ Mn) Analysis by End User, 2016-2032 Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2022-2032 Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2022-2032 Figure 58: Europe Market Attractiveness by Route of Administration, 2022-2032 Figure 59: Europe Market Attractiveness by End User, 2022-2032 Figure 60: Europe Market Attractiveness by Country, 2022-2032 Figure 61: Asia Pacific Market Value (US$ Mn) by Route of Administration, 2022-2032 Figure 62: Asia Pacific Market Value (US$ Mn) by End User, 2022-2032 Figure 63: Asia Pacific Market Value (US$ Mn) by Country, 2022-2032 Figure 64: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2016-2032 Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 67: Asia Pacific Market Value (US$ Mn) Analysis by Route of Administration, 2016-2032 Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032 Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032 Figure 70: Asia Pacific Market Value (US$ Mn) Analysis by End User, 2016-2032 Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by End User, 2022-2032 Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by End User, 2022-2032 Figure 73: Asia Pacific Market Attractiveness by Route of Administration, 2022-2032 Figure 74: Asia Pacific Market Attractiveness by End User, 2022-2032 Figure 75: Asia Pacific Market Attractiveness by Country, 2022-2032 Figure 76: MEA Market Value (US$ Mn) by Route of Administration, 2022-2032 Figure 77: MEA Market Value (US$ Mn) by End User, 2022-2032 Figure 78: MEA Market Value (US$ Mn) by Country, 2022-2032 Figure 79: MEA Market Value (US$ Mn) Analysis by Country, 2016-2032 Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 82: MEA Market Value (US$ Mn) Analysis by Route of Administration, 2016-2032 Figure 83: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032 Figure 84: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032 Figure 85: MEA Market Value (US$ Mn) Analysis by End User, 2016-2032 Figure 86: MEA Market Value Share (%) and BPS Analysis by End User, 2022-2032 Figure 87: MEA Market Y-o-Y Growth (%) Projections by End User, 2022-2032 Figure 88: MEA Market Attractiveness by Route of Administration, 2022-2032 Figure 89: MEA Market Attractiveness by End User, 2022-2032 Figure 90: MEA Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
